Q1 2022

Filed May 10, 2022 · 10-Q · 40 days after period end · 0001410578-22-001218

Q1 2022 · 10-Q

Revenue

$403.00K

+68.6% vs Q1 2021

Net Income

-$14.21M

N/M vs Q1 2021

EPS Diluted

-$0.01

— vs Q1 2021

Operating Income-$12,286,000N/M

Operating Cash Flow

Same quarter

Metric	Q1 2022	Q1 2021	Q1 2020	Q1 2019
Revenue	$403.00K	$239.00K	$570.00K	$339.00K
Net Income	-$14.21M	-$4.12M	$2.73M	-$20.95M
EPS Diluted	-$0.01	$0.00	$0.00	-$0.04

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR